Zimberelimab
- Generic Name
- Zimberelimab
- Drug Type
- Biotech
- CAS Number
- 2259860-24-5
- Unique Ingredient Identifier
- ZBL7O904IL
- Indication
用于治疗二线以上复发或难治性经典型霍奇金淋巴瘤（r/r cHL）患者。
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Conditions
- Solid TumorsClear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 302
- Registration Number
- NCT05536141
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California at San Diego, San Diego, California, United States
🇺🇸Medical Oncology Associates Summit Cancer Centers, Spokane, Washington, United States
GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)
- Conditions
- Refractory Classic Hodgkin LymphomaRecurrent Classic Hodgkin LymphomaClassic Hodgkin's Lymphoma
- Interventions
- Drug: Chemotherapy of Investigator's choice
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05518318
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1069
- Registration Number
- NCT05502237
- Locations
- 🇨🇳
West China Hospital Sichuan University, Chengdu, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, China
🇨🇳Deyang People's Hospital, Deyang, China
Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
- Conditions
- Locally Advanced Cervical Cancer
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT05437692
- Locations
- 🇨🇳
Shanghai Zhongshan hospital, Shanghai, Shanghai, China
Switch Maintenance in Pancreatic
- Conditions
- Pancreatic CancerAdenocarcinoma of the PancreasSquamous Cell Carcinoma of PancreasAdenosquamous Carcinoma of the Pancreas
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- James Cleary, MD, PhD
- Target Recruit Count
- 46
- Registration Number
- NCT05419479
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
- Conditions
- Urothelial CarcinomaMetastatic Cancer
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05335941
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
- Conditions
- Gastrointestinal Tract Malignancies
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 333
- Registration Number
- NCT05329766
- Locations
- 🇫🇷
Institut Bergonié _ Bordeaux, Bordeaux, France
🇫🇷CHU de Brest_Brest, Brest, France
🇫🇷Centre Baclesse - CAEN, Caen Cedex 5, France
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
- Conditions
- Prostate CancerMetastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05177770
- Locations
- 🇺🇸
START South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸START Mountain Region, Utah Cancer Specialists, West Valley City, Utah, United States
🇨🇦BC Cancer - The Vancouver Centre, Vancouver, British Columbia, Canada
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Diwakar Davar
- Target Recruit Count
- 26
- Registration Number
- NCT05130177
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
- Conditions
- Rectal Cancer
- Interventions
- Radiation: Radiation therapyDrug: FOLFOX regimen
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 43
- Registration Number
- NCT05024097
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸Brooklyn Methodist Hospital - NewYork Presbyterian, New York, New York, United States
🇺🇸New York Presbyterian Hospital - Queens, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.